Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment after endocrine therapy, according to results from the phase III ASCENT-07 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant  given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer, according to the results of the phase III IidERA trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

University of South Australia scientists have developed a powerful new way to uncover the genetic interactions that fuel cancer progression, paving the way for earlier and more precise treatments.

Children who grow up in farming communities have long been known to develop far fewer allergies than their urban peers. A new study from the University of Rochester Medical Center (URMC), offers one possible reason why: their immune systems may mature faster, and breast milk appears to play an important supporting role.

The compound, called I3IN-002, disrupts the ability of a protein known as IGF2BP3 to bind and stabilize cancer-promoting RNAs, a mechanism that fuels aggressive forms of acute leukemia.

Reducing calorie intake helps cancer-fighting immune cells do their jobs more effectively, reports a study by Van Andel Institute scientists and collaborators. The findings lay the groundwork for developing dietary strategies to boost the effects of a powerful class of cancer immunotherapies.

This cohort study of older traditional Medicare beneficiaries who were diagnosed with common metastatic cancers found a mean of 40 to 62 health care contact days in the year after diagnosis. Health care contact days increased from 2008 to 2019, suggesting that treatment advancements and/or care inefficiencies may have imposed additional burdens on beneficiaries. The results of this study suggest that oncology teams should discuss expected contact days and related burdens when developing care goals and treatment plans with older adult patients.